-0.77%
-8.90%
-26.12%
-8.04%
60.08%
37.46%
78.44%
AI Spotlight on OCUL
Company Description
Ocular Therapeutix, Inc., a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology.The company markets ReSure Sealant, an ophthalmic device to prevent wound leaks in corneal incisions following cataract surgery; and DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.It is also developing OTX-TKI, an axitinib intravitreal implant that is in phase 1 clinical trials for the treatment of wet age-related macular degeneration and other retinal diseases; OTX-TIC, a travoprost intracameral implant, which is in phase 2 clinical trials for the treatment of open-angle glaucoma or ocular hypertension; OTX-CSI, a cyclosporine intracanalicular insert that has completed phase 2 clinical trials for the treatment of dry eye disease; and OTX-DED, a dexamethasone intracanalicular insert, which is in phase 2 clinical trials for the short-term treatment of the signs and symptoms of dry eye disease.
The company has a strategic collaboration with Regeneron Pharmaceuticals, Inc.(Regeneron) for the development and commercialization of products using the Company's sustained-release hydrogel in combination with Regeneron's large molecule VEGF-targeting compounds for the treatment of retinal diseases; and AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and OTX-TIC, as well as a discovery collaboration with Mosaic Biosciences to identify new targets and therapeutic agents for the treatment of dry age-related macular degeneration (dMAD).Ocular Therapeutix, Inc.
was incorporated in 2006 and is headquartered in Bedford, Massachusetts.
Market Data
| Last Price | 7.78 |
| Change Percentage | -0.77% |
| Open | 7.94 |
| Previous Close | 7.84 |
| Market Cap ( Millions) | 1223 |
| Volume | 1439718 |
| Year High | 11.78 |
| Year Low | 4.06 |
| M A 50 | 8.75 |
| M A 200 | 8.07 |
Financial Ratios
| FCF Yield | -9.33% |
| Dividend Yield | 0.00% |
| ROE | -56.75% |
| Debt / Equity | 21.34% |
| Net Debt / EBIDTA | 225.82% |
| Price To Book | 3.69 |
| Price Earnings Ratio | -7.45 |
| Price To FCF | -10.72 |
| Price To sales | 19.93 |
| EV / EBITDA | -5.59 |
News
- Jan -17 - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Jan -14 - Ocular Therapeutix™ Shares SOL-R Enrollment Progress and Next Steps for AXPAXLI™ in NPDR
- Dec -30 - Ocular Is Now Thoroughly Derisked
- Dec -13 - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Dec -10 - Ocular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Dec -02 - Ocular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1
- Nov -26 - Ocular Therapeutix™ to Participate in December Investor and Scientific Conferences
- Nov -14 - Ocular Therapeutix (OCUL) Reports Q3 Loss, Lags Revenue Estimates
- Nov -13 - Ocular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIV
- Nov -06 - Ocular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024
- Oct -15 - Ocular Therapeutix™ Announces Accelerated Timelines for SOL-1 Registrational Trial of AXPAXLI™ in Wet AMD
- Oct -14 - Ocular Therapeutix (OCUL) Moves 6.1% Higher: Will This Strength Last?
- Oct -11 - Ocular Therapeutix: Focus On Axpaxli's Path To Market In Wet-AMD And Implications To Investors
- Oct -09 - Ocular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
- Oct -09 - Ocular Therapeutix™ to Present at October Ophthalmology Meetings
- Sep -25 - Ocular Therapeutix™ to Present at the UBS Virtual Opthalmology Day 2024
- Sep -05 - Ocular Therapeutix™ to Present at September Retina Meetings
- Sep -04 - Ocular Therapeutix™ to Present at Two Investor Conferences in September
- Aug -09 - Ocular Therapeutix, Inc. (OCUL) Q2 2024 Earnings Call Transcript
- Aug -09 - Wall Street Analysts See an 85.43% Upside in Ocular Therapeutix (OCUL): Can the Stock Really Move This High?
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Bioresorbable Hydrogel Platform Technology
Expected Growth : 9.27 %
What the company do ?
Ocular Therapeutix's Bioresorbable Hydrogel Platform Technology is a sustained-release drug delivery system that uses a biodegradable hydrogel to deliver therapeutic agents to the eye.
Why we expect these perspectives ?
Ocular Therapeutix's Bioresorbable Hydrogel Platform Technology growth is driven by increasing demand for minimally invasive ophthalmic treatments, rising prevalence of eye disorders, and growing adoption of innovative drug delivery systems. Additionally, strategic partnerships, expanding product pipeline, and regulatory approvals are contributing to the 9.27% growth.
Segment n°2 -> Collaboration
Expected Growth : 8.5 %
What the company do ?
Ocular Therapeutix, Inc. collaborates with pharmaceutical companies to develop sustained-release implants for back of the eye diseases, enhancing treatment outcomes.
Why we expect these perspectives ?
Ocular Therapeutix, Inc.'s 8.5% growth is driven by increasing adoption of its innovative ocular implant, DEXTENZA, for post-operative ocular inflammation and pain. Strong partnerships, expanded commercialization efforts, and growing demand for minimally invasive treatments also contribute to this growth. Additionally, the company's pipeline of novel therapeutics and devices for ocular diseases supports future growth prospects.
Ocular Therapeutix, Inc. Products
| Product Range | What is it ? |
|---|---|
| Dextenza | A corticosteroid intracanalicular implant for the treatment of post-operative inflammation and pain associated with cataract surgery. |
| OTX-TP | A sustained-release travoprost intracameral implant for the reduction of intraocular pressure in patients with primary open-angle glaucoma or ocular hypertension. |
| OTX-TIC | A sustained-release triamcinolone intravitreal implant for the treatment of diabetic macular edema. |
Ocular Therapeutix, Inc.'s Porter Forces
Threat Of Substitutes
The threat of substitutes for Ocular Therapeutix, Inc. is medium due to the presence of alternative treatments and products in the ophthalmic space. However, the company's proprietary hydrogel technology and FDA-approved products provide a competitive advantage.
Bargaining Power Of Customers
The bargaining power of customers for Ocular Therapeutix, Inc. is low due to the company's focus on providing innovative and effective treatments for ophthalmic conditions, which gives it a strong negotiating position with customers.
Bargaining Power Of Suppliers
The bargaining power of suppliers for Ocular Therapeutix, Inc. is medium due to the company's reliance on a few key suppliers for raw materials and manufacturing services. However, the company's strong relationships with suppliers and its ability to negotiate favorable terms mitigate this risk.
Threat Of New Entrants
The threat of new entrants for Ocular Therapeutix, Inc. is high due to the growing demand for ophthalmic treatments and the increasing interest in the space from large pharmaceutical companies and startups. However, the company's strong intellectual property portfolio and regulatory approvals provide a barrier to entry for new entrants.
Intensity Of Rivalry
The intensity of rivalry for Ocular Therapeutix, Inc. is high due to the competitive nature of the ophthalmic industry, with multiple companies vying for market share. However, the company's innovative products and strong commercialization efforts position it well to compete in this environment.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 45.64% |
| Debt Cost | 11.24% |
| Equity Weight | 54.36% |
| Equity Cost | 11.24% |
| WACC | 11.24% |
| Leverage | 83.96% |
Ocular Therapeutix, Inc. : Quality Control
Ocular Therapeutix, Inc. passed 5 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| EYPT | EyePoint Pharmaceuticals, Inc., a pharmaceutical company, develops and commercializes ophthalmic products for the treatment of eye diseases in the United States, China, and the United Kingdom. The company provides ILUVIEN, … |
| PSTX | Poseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company develops P-PSMA-101, an autologous chimeric antigen receptor T cell (CAR-T) … |
| ABUS | Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of … |
| BCRX | BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the … |
| GTHX | G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Ocular Therapeutix
A-Score
1-Year Total Return ->
🥈
Arbutus Biopharma
A-Score
1-Year Total Return ->
🥉
BioCryst Pharmaceuticals
A-Score
1-Year Total Return ->
4
Poseida Therapeutics
A-Score
1-Year Total Return ->
5
G1 Therapeutics
A-Score
1-Year Total Return ->
6
